☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Legend
Legend’s Carvykti (ciltacabtagene autoleucel) Receives the EC’s Approval for the Treatment of Relapsed and Refractory Multiple Mye...
May 26, 2022
PharmaShots Interview: Legend's Ying Huang Shares Insight on ASH 2020 Data and Initiation of BLA Rolling Submission for Cilta-cel
February 25, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.